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The clinical significance of parathyroid hormone-related protein in humoral hypercalcemia of
malignancy was investigated by determining the serum parathyroid hormone-related protein
concentrations in 167 normal subjects, 56 patients with hematologic malignancy and 144 patients
with solid tumor. Serum parathyroid hormone-related protein was measured with a radioimmunoas-
say kit that recognizes the C-terminal portion of the molecule. The serum parathyroid hormone-related
protein concentrations were 20.2-50.8 pmol/l (mean + 2 so) in normal subiects, and were elevated in
8O% of the patients with malignancies with hypercalcemia, including squamous cell carcinoma and
adult T cell leukemia. Moreover, two cases of B cell non-Hodgkin's lymphoma with hypercalcemia had
high serum parathyroid hormone-related protein concentrations, which varied in parallel with the
tumor size during the clinical course. Of 136 patients with solid tumors with normocalcemia, the serum
parathyroid hormone-related protein concentration was slightly elevated in only 5.1o/o, all of whom
were at an advanced stage. These data indicate that determination ofthe serum parathyroid hormone-
related protein concentration is useful for diflerential diagnosis of humoral hypercalcemia of
malignancy and prediction of its development.
Yuriko Nakamura, First Departrnent of Internal Medicine, School of Medicine, University ol Tokushima,
Kuramoto-cho 3-18-15. Tokushima 770, lapan
In 1987, four groups (1-4) purified parathyroid hor-
mone-related protein (PTHTP) and Suva et al. (5) cloned
and sequenced the gene of this protein. In addition,
immunoreactive PTHrP was demonstrated in an extract
of a humoral hypercalcemia of malignancy tumor (6, 7)
by radioimmunoassay (RIA). In 1990, Burtis et al. (8)
developed an immunoradiometric assay (IRMA) for
PTHrP (1-74) and an RIA for PTHrP (109-138), and
reported that both their assays were useful in the
differential diagnosis of hypercalcemia. The value of
determining urinary PTHrP 0.27-147) was also
reported (9). However, the serum PTHrP levels in
normal subjects are difficult to measure by these assays,
and there have been few reports on the relationship
between the clinical course and serum PTHrP level.
Recently, Kasahara et al. (10) developed an RIA kit for
PTHrP (109-141) with which we could measure the
serum PTHrP concentrations in normal subjects and in
patients with various diseases. Here we report data on
the serum PTHrP concentrations in patients with hema-
tologic malignancies or solid tumors who had normal
serum creatinine levels, and the relationship between
the clinical course and change in serum PTHTP.
Subjects and methods
Subjects
The subjects examined were 167 normal adults (92M,
75F) aged 20-60 years, 56 patients with hematologic
malignancy and 144 patients with solid tumor.
Serum calcium was measured using the O-cresolph-
thalein complexing method after an overnight fast. The
serum calcium concentration was corrected by the
equation, "corrected calcium: measured calcium (mg/
dl)+4.0-albumin (g/dl)" and values in mg/dl were
converted to mmol/I. Normal range of serum calcium
was 2.25 +0.20 mmol/l (meant2 so). Hypercalcemia
was defined as a serum calcium level of above 2.65
mmol/l (mean+4 so).
Serum creatinine u/as measured by Jaff6's test. No
significant difference was observed between serum
creatinine concentrations in normal subjects and
tumor patients (mean * 2 so, 79.7 t26.6 vs 79.6 +77 .7
pmol/l).
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Fig. 1. Serum PTHrP concentrations in normal subiects and in patients with various hematologic malignancies. The bar indicates the mean + 2 sn
in normal subiects. Each point represents serum PTHrP concentration in patients with hypercalcemia (o) or normocalcemia (o).
?able 1. Clinical stage in the patients with solid tumor who had normocalcemia and elevation of serum PTHrP level.
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SCC: squamous cell carcinoma; adeno ca.: adenocarcinoma.
Determination of serum PTHrP
Serum PTHrP concentration was measured with a
PTHrP kit (D-0i02, Daiichi Radioisotope Institute,
Tokyo, Japan) (10). The kit is composed of antibody
raised against human PTHrP (109-141), r2sl-labelled
[Tyr108]-PTHTP (108-141) and synthetic human PTHrP
(109-141) as a standard. As reported previously (10),
100 pl of r2sl-labelled PTHrP (108-141) and 100 pl of
antibody were incubated with 2OO pl of a standard
solution or sample for 22 h. Then the second antibody
(anti-sheep donkey IgG antibody) was added, and incu-
bation was continued for 30 min. The mixture was then
centrifuged, the supernatant removed by aspiration, and
the radioactivity of the residue measured. By this assay
the detectable range is 10-1000 pmol/I. The intra-assay
and interassay coefficients of variation were found to be
7.91-5.94% and 2.75-3.82% at concentrations of 39
and 330 pmol/I, respectively, and the recoveries of
PTHrP added to serum samples at concentrations of 15,
50, 150 and 500 pmol/l were 98.5 to 7O5.7%.
Statistical analAsis
Student's t-test was used to compare serum PTHrP levels
in two groups, and a p value of less than 0.05 was
considered to indicate statistical significance.
Results
Serum PTHrP concentrations
Normal subjects. The serum PTHrP concentrations of
1 6 7 normal subjects were distributed lognormally in the
range of 20.2-5O.8 pmol/l (mean + 2 so) after logarith-
mic transformation. No significant difference was
observed between the values of males and females.
Patients with hematologic malignancy. Of 5 6 patients with
hematologic malignancy, 7 patients (2 with malignant
Iymphoma, 3 with leukemia, 2 with myeloma) had
hypercalcemia. Of these patients, 2 with B cell non-
Hodgkin's lymphoma, I with adult T cell leukemia and 1
with myeloma had high serum PTHrP concentrations
(Fie. 1).
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Pituitary adenoma (N : 31) 書
Oral squamous cell carcinoma (N : 39) ‐ 0       00   0
Oral adenocarcinoma (N = 5) ■ 0
Lung squamous cell carcinoma (N = 8) -000   0
Lungadenocarcinoma (N:9) 夕 。
Lung small cell carcinoma (N = 3) 00 0
Gastric cancer (N = 9) ● 。
Colon cancer (N : 5) 00
Hepatocellular carcinoma (N = 17) 00
Gallbladder carcinoma (N = 2)
“
Pancreas cancer (N = 5) ●
Benal cell carcinoma (N : 2)
Prostatic cancer (N = 1)
Adrenocortical cancer (N = 2)
Uterus cancer (N = 1)
Ovarian cancer (N = 2) 0
Malignant melanoma (N = 2) ∞
Malignantthymoma (N:1) 0
t'ig. 2. Serum PTHrP concentrations in 144 patients with various solid tumors. Each point represents serum PTHrP concentration in patients with
hypercalcemia (o) and normocalcemia (a).































































l'ig. 3. Clinical course of Case 1. The levels of serum calcium (Ca) (o), serum PTHrP (O) and urinary PTHrP (r) are shown. The shaded area
represents the normal range of serum calcium level. MACOP-B: adriamycin, cyclophosphamide, vincristine, bleomycin and prednisolone. POEM:
vincristine, etoposide, mitoxantrone and prednisolone,
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l'ig. 4. Immunoperoxidase staining of a lymph node with anti PTHrP
(34-53) antibody.'Immunoactive PTHrP was found in the cytoplasm
of the lymphoma cetls ( x 400).
Of 22 patients with malignant lymphoma' 2 patients
with high serum PTHrP concentration were advanced
cases at clinical stage IV.
Patients with solid tumor. Of 144 patients with solid
tumor, 8 patients had hypercalcemia' AII of them had
high serum PTHrP concentrations.
Of 136 patients with solid tumors with normocalce-
mia, only 7 patients had slightly elevated serum PTHrP
levels (Table 1),
In patients with lung cancer, the serum PTHrP
concentration was 37.1-181.8 pmol/l in eight with
squamous cell carcinoma, 20.2-48.7 pmol/l in nine
with adenocarcinoma and 22.7-43.8 pmol/l in three
with small cell carcinoma, the increase in those with
squamous cell carcinoma being significant. The serum
PTHrP concentration was within normal limits in all
patients with malignancies in the gastrointestinal sys-
tem, liver, gall bladder or pancreas (Fig. 2). One patient
with prostatic cancer showing osteoblastic metastasis
had a serum PTHrP concent'rationof 242.4 pmol/I, but a
normal serum calcium level. The serum PTHrP concen-
trations in patients with pituitary adenoma, including
11 with acromegaly, 7 with Cushing's disease, 4 with
prolactinoma, 5 with nonfunctional adenoma and 4
with craniopharyngioma, were within the normal range
(Fie. 2).
Changes in serum PTHrP concentrations during the
clinical courses of three patients
Case 7. A 59-year-old male was diagnosed as having
diffuse, large cell type, B cell non-Hodgkin's lymphoma
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by lymph node biopsy in June 1991. On fuly 31, the
patient became somnolent and was admitted to this
hospital. He was judged to be in stage IVb and found to
have swelling of the cervical and axillary Iymph nodes,
jaundice, hepatomegaly, ascites and hypercalcemia
(3.2 5 mmol/l). His serum and urinary PTHrP levels were
markedly elevated (Fig. 3). Anti-HTLV-I antibody titers
were negative. After chemotherapy with MACOP-B, the
lymphadenopathy, jaundice, hepatomegaly and ascites
disappeared, his serum and urinary PTHrP levels de-
creased and his serum calcium concentration was
normalized. Thus, complete remission (CR) was
obtained. However, his serum and urinary PTHrP Ievels
began to increase from November and axillary Iymph
node swelling reappeared in December. Chemotherapy
with POEM resulted in slight decreases in the size of the
lymph nodes and the serum PTHrP concentration.
The malignant cells in the formalin-fixed, paraffin-
embedded section of a lymph node showed positive
immunoreactivity for two types of antibody, one raised
against PTHrP (34-53) (Oncogene Science, NY) (Fig.  ),
and the other against PTHrP (109-141) (Daiichi Radio-
isotope Institute. Tokyo, fapan). These large tumor cells
were also stained with anti-B cell antibody L26, but not
with anti-T cell antibody UCHL-I, indicating that they
were B cells. This lymph node was obtained at biopsy in
June 1991.
Case 2. A 68-year-old male was diagnosed as having
diffuse, large cell type, B cell non-Hodgkin's lymphoma
by lymph node biopsy in March, 1991. When admitted
to our hospital in September, he was judged to be in stage
IVb and showed disturbance of consciousness, swelling
of the cervical, axillary and inguinal lymph nodes and
hypercalcemia (3.40 mmolil). Anti-HTLV-I antibody
titers were negative. His serum PTHrP concentration
was 461.5 pmol/I. After chemotherapy with MACOP-B,
the lymphadenopathy subsided and the serum PTHrP
concentration decreased to 34.1 pmol/l and his serum
calcium concentration (2.27 mmol/l) was normalized.
However, the patient died of sepsis on 9 October.
Case 3. A 54-year-old male with cheek swelling was
diagnosed as having squamous cell carcinoma of the
maxillary sinus in August, 1988. His serum PTHrP
concentration was slightly elevated to 64.0 pmol/I, but
the serum calcium level was normal (Fig. 5). After
operation, he received chemotherapy and radiation
therapy, resulting in decrease of the tumor size and of the
serum PTHrP concentration in June, 1989. However,
subsequently his serum PTHrP concentration increased
almost in parallel with enlargement of the tumor and the
serum squamous cell carcinoma-related antigen (SCC)
level. Hypercalcemia developed in December, 1990 and
he died of respiratory failure due to multiple metastasis
in the lung.







Burt et al. ( 1 1 ) reported that the incidence of hypercalce-
mia in patients with malignancy is about 8.5o/o, and is
similar in patients with solid tumors and hematologic
malignancies. There are also reports of association of
hypercalcemia with hematologic malignancy in about
30% of myeloma patients , 40% of adult T cell leukemia
patients, 13% of leukemia patients, and 5.6Yo (12) or
1.8% (13) of malignant lymphoma patients.
PTHrP has been implicated as the main causal factor
of humoral hypercalcemia of malignancy. Since the
determination of its amino acid seqeunce by Suva et al.
(5) in 1987, several methods for its determination have
been developed for study of the mode of its production
and secretion.
Budayr et al. (14) developed an RIA for PTHrP (1-34)
in 1989, and reported high serum PTHrP (1-34)
concentrations in 30 (71%) of 42 patients with solid
tumors associated with hypercalcemia. Most of these
tumors were squamous cell carcinomas and renal
cancers. They also found that 23 patients with normo-
calcemia nearly all had a normal serum PTHrP concen-
tration. Similarly, Kao et al. (15) observed elevated
plasma PTHrP (1-34) concentrationsin 47/o of patients
with cancer associated with hypercalcemia. In 1990,
Burtis et al. (8) developed an IRMA for PTHrP (1-74)
and an RIA for PTHrP (109-138), and reported that the
plasma PTHrP concentration was markedly increased in
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humoral hypercalcemia of malignancy patients, but not
in cancer patients with normocalcemia or local osteoly-
tic hypercalcemia patients, and that the plasma PTHrp
concentration was low or undetectable in 60 normal
subjects. Therefore, he suggested that determination of
the plasma PTHrP concentration was useful for diagno-
sis of humoral hypercalcemia of malignancy. Henderson
et al. (16) reported similar findings. However, it is
difficult to measure the serum PTHrP concentrations in
normal subjects or patients with tumors with normocal-
cemia by these assays, and so there have been few
reports on the changes in serum PTHrP levels in patients
during their clinical course.
In this study, we could measure serum PTHrp concen-
trations in normal subjects and patients by an RIA for
PTHrP (109-141) developed by Kasahara et al. (10).
This RIA can detect as little as 2 pmol/l of PTHrp, and its
specificity and reproducibility are excellent. We found
that the serum PTHrP concentrations in 167 normal
subjects were 20.2-50.8 pmol/I. Seven of 56 patients
with haematologic malignancy had hypercalcemia, and
4 of them (2 with malignant lymphoma, 1 with adult T
cell leukemia and 1 with myeloma) had very high serum
PTHrP concentrations. These data are consistent with
reported findings (14, 17, 18). Moreover, our series
included a patient with B cell non-Hodgkin's lymphoma
in whom the serum PTHrP concentration was elevated
and production of PTHrP by the lymphoma cells was
demonstrated immunohistochemically. This seems to be


















































































F'ig. 5. Clinical course of Case 3. The serum levels of PTHrP (o), squamous cell carcinoma-related antigen (SCC) (r) and calcium (Ca) (o) are
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the first report of a PTHrP-producing B cell type
lymphoma.
There are reports of PTHrP production in a number of
malignant cell lines and in solid tumors causing
humoral hypercalcemia of malignancy. In this study, 8
of 144 patients with solid tumors had hypercalcemia
and markedly high serum PTHrP (1O9-141) concentra-
tions. These findings confirm the conclusion that deter-
mination of the serum PTHrP (109-141) is useful for
diagnosis of humoral hypercalcemia of malignancy.
Increased serum PTHrP concentrations were found in
80% of the patients with malignancy with hypercalce-
mia, indicating that most of these malignancies with
hypercalcemia were due to PTHrP production. In the
other cases, several other factors may have been
involved, such as interleukin-1 (19), osteoclast activat-
ing factor (20), prostaglandins (21) and transforming
growth factor (22).
The other 136 patients with solid tumors had normo-
calcemia. but the serum PTHrP concentration was
slightly elevated in seven patients (three with oral
squamous cell carcinoma, three with lung squamous
cell carcinoma and one with prostatic cancer). All these
seven patients were advanced cases at clinical stage III or
IV. Only one of these seven patients later became
hypercalcemic with enlargement of the tumor. These
findings may be explained by the differences in the
duration of elevated PTHrP levels and in the capacity of
calcium excretion in these patients. Of 20 patients with
lung cancer, the serum PTHrP concentration was
significantly higher in those with squamous cell carci-
noma than in those with adenocarcinoma or small cell
carcinoma. These findings are consistent with reports
that PTHrP was released into the culture medium of
human keratinocytes (23), and that well differentiated
squamous cell carcinomas were stained with anti-
PTHrP antibody but adenocarcinomas were not irres-
pective of the serum calcium Ievel (24).
Prostatic cancer is rarely associated with hypercalce-
mia because it is liable to show osteoblastic metastasis.
Raskin et al. (25) reported that more than 30olo of
patients with prostatic cancer with bone metastasis had
hypocalcemia, and that no cases had hypercalcemia. In
this study, one patient with osteoblastic metastasis had a
high serum PTHrP concentration, but a normal serum
calcium level. These findings may reflect the balance
between osteogenesis due to osteoblastic metastasis and
bone resorption due to PTHTP.
An interesting finding was that in a patient with oral
squamous cell carcinoma with normocalcemia, the
serum PTHrP level began to increase in parallel with
enlargement of the tumor but before increase in the
serum calcium concentration. This flnding shows that
determination of serum PTHrP is also useful for predict-
ing development of humoral hypercalcemia of malig-
nancy, and that the serum PTHrP concentration can be
used as one of the tumor markers.
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